New shot could shrink enlarged livers and ease pain
NCT ID NCT05281328
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called CAM2029 (octreotide) given as a weekly or every-other-week shot to people with symptomatic polycystic liver disease. The goal is to see if it can shrink the liver and reduce symptoms like belly pain, bloating, and nausea. About 71 adults with an enlarged liver will be randomly assigned to receive the drug or a placebo for 53 weeks, with an option to continue on the drug for another 120 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYSTIC LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bon Secours Richmond Community Hospital
Richmond, Virginia, 23602, United States
-
Hannover Medical School
Hanover, 30625, Germany
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
Radboud UMC, Department of Gastroenterology and Hepatology
Nijmegen, 6525 GA, Netherlands
-
The New York Presbyterian Hospital
New York, New York, 10065, United States
-
Universitaetsklinikum Müenster
Münster, 48149, Germany
-
University Hospitals KU Leuven
Leuven, B-3000, Belgium
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75380-8887, United States
-
Universitätsklinikum Leipzig
Leipzig, 04103, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.